Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Polaryx Therapeutics, Inc. (PLYX)

Polaryx Therapeutics CMO Lisa Bollinger resigns effective immediately

Neutral Impact 4 of 5 leadership Written later

Polaryx Therapeutics said its Chief Medical Officer, Lisa Bollinger, MD, resigned on July 19, 2026, effective immediately. The company said the departure is not expected to affect previously disclosed clinical timelines, regulatory plans or development strategy, and it has started searching for a successor.

Key points

  • Lisa Bollinger, MD, resigned as Chief Medical Officer on July 19, 2026, effective immediately
  • Company does not anticipate effects on previously disclosed clinical timelines, regulatory plans or development strategy
  • Responsibilities will be assumed by existing leadership team members in the interim
  • Search for a successor has commenced

The filing

CompanyPolaryx Therapeutics, Inc. (PLYX)
Form8-K, current report
Filed with the SECJul 21, 2026, 4:30 PM ET
Accession number0001213900-26-080041

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 21, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.